Sidewinder Therapeutics

Stub active Updated Apr 8, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Diego, California
Founded 2023
Latest Stage Series B
Total Raised $137M
Website https://www.sidewindertx.com
Sector
biotech oncology antibody-drug-conjugates

Investors

frazier-life-sciences series-b (2026)
novartis-venture-fund series-b (2026)
orbimed series-b (2026)
dcvc-bio series-b (2026)
samsara-biocapital series-b (2026)
longwood-fund series-b (2026)
astellas-venture-management series-b (2026)
alexandria-venture-investments series-b (2026)

Founders

Eric Murphy Co-Founder & CEO

About

Sidewinder Therapeutics is a San Diego-based biotech company founded in 2023 that develops next-generation bispecific antibody-drug conjugates (ADCs) designed to target receptor co-complexes found in solid tumors 1. The company aims to target tumors more precisely and reduce damage to healthy tissue 1. Sidewinder plans to advance its lead program into clinical development in 2027 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-08 Series B $137M Frazier Life Sciences, Novartis Venture Fund OrbiMed, DCVC Bio, Goldman Sachs Alternatives, Samsara BioCapital, Longwood Fund, Astellas Venture Management, Alexandria Venture Investments 12

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. Ventureburn, “Sidewinder Therapeutics Raises $137M to Advance Bispecific,” accessed April 2026. https://ventureburn.com/sidewinder-therapeutics-137m/↩↩↩↩

  2. BusinessWire, “Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer,” April 8, 2026. https://www.businesswire.com/news/home/20260408583837/en/Sidewinder-Therapeutics-Announces-$137-Million-Series-B-Financing-to-Advance-Precision-Bispecific-ADCs-into-Clinical-Development-for-Cancer↩